Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dual-Trained Rheumatologists Take Multidisciplinary Approach to Their Patients

Gretchen Henkel  |  Issue: October 2015  |  October 14, 2015

Dr. Dellaripa co-founded the Interstitial Lung Disease (ILD) clinic with pulmonologist Hilary Goldberg, MD. The clinic uses a multidisciplinary model to treat patients with inflammatory and fibrotic lung disease. The staff, comprising rheumatologists, pulmonologists, pathologists and radiologists, focus on diagnosing and treating patients with ILD, providing same-day consultations and evidence-based protocols developed from the clinic’s treatment algorithm.

Nine years ago, Dr. Dellaripa initiated a lung-disease-in-rheumatology study group through the ACR, which quickly included both national and international researchers. This group has developed outcome measures particular to patients with lung and rheumatic disease and is now beginning to develop prospective trials. “The goal is to identify at-risk patients for lung disease and limit the morbidity and mortality of this complication,” he says. “When these patients get ill and end up in the ICU, their survival is not great, so early identification and intervention, when appropriate, are important.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Challenges of Complexity

Vladimir N. Despotovic, MD, assistant professor of medicine at Washington University in St. Louis, another dual-trained rheumatologist, first came to the U.S. in 1992 as an exchange student at the age of 17. He lived in Michigan for three years and then returned to Serbia in 1995 and enrolled in medical school in Belgrade. He returned to the U.S. in 1999 due to the political and economic environment in the Balkans.

Dr. Despotovic

Dr. Despotovic

Although Dr. Despotovic briefly considered a major in mathematics, he was also drawn to medicine. “Both my father and older sister are physicians, so I had great role models throughout my youth,” he says. “My sister wanted me to become an ophthalmologist like her, but I enjoyed the more broad, hands-on internal medicine approach.” His father is an internist, and it was from him that Dr. Despotovic acquired “the love of pathophysiology and immunology, which are my interests to this day.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Once back in the U.S., he resumed his pre-med studies at Michigan State University in East Lansing. He notes that during his medical training at Wayne State University and subsequent internship and residency at Washington University, he liked most medical subspecialties and was “interested in everything.” His wide-ranging interests have been both “a blessing and a curse for me my whole career,” he says. What eventually drew him to rheumatology was the prominent part played by immunology and the clinical complexity of rheumatologic disorders. “I liked the fact that, as a medical resident, whenever we would have a complex patient, we often called rheumatology for a consult,” he says. “I wanted to be the person who understands that complexity.”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Career DevelopmentConditionsProfessional TopicsRheumatoid Arthritis Tagged with:ClinicalDiagnosislung disorderpatient careRARheumatoid arthritisrheumatologistrhuematologyTreatment

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    New Africa / shutterstock.com

    A Rheumatologist & Pulmonologist Discuss RA-ILD

    November 14, 2021

    Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

    Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

    September 22, 2021

    Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences